arrow
L

Leon D. Kaulen

massachusetts general hospital
H指数:14
被引数:2,014

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Immunodeficiency-associated primary CNS lymphomas: An International Primary CNS Lymphoma Collaborative Group (IPCG) Study

免疫缺陷相关性原发性中枢神经系统淋巴瘤:一项国际原发性中枢神经系统淋巴瘤协作组(IPPC)研究

Blood
IF23.1
2026-03-200
OAAI
Patterns, risk factors and management of CD19-directed chimeric antigen receptor T-cell therapy failure in CNS lymphoma

中枢神经系统淋巴瘤CD19-directed嵌合抗原受体T细胞治疗失败的模式、危险因素及处理

2026-01-140
OAAI
Clinical Presentation, Management and Outcome of Tumor inflammation-associated neurotoxicity (TIAN) in CNS lymphoma treated with CD19-CAR T-cell therapy

肿瘤炎症相关神经毒性(TIAN)在经CD19-CAR T细胞疗法治疗的CNS淋巴瘤中的临床表现、管理与转归

2025-11-010
OAAI
Distinct epigenetic and transcriptional profiles of Epstein-Barr virus (EBV) positive and negative primary CNS lymphomas

EBV阳性与阴性原发性中枢神经系统淋巴瘤的表观遗传和转录谱存在差异

2025-11-010
OAAI
DISTINCT EPIGENETIC AND TRANSCRIPTIONAL PROFILES OF EPSTEIN-BARR VIRUS (EBV) POSITIVE AND NEGATIVE PRIMARY CNS LYMPHOMAS

EBV阳性与阴性原发性CNS淋巴瘤的差异性表观遗传和转录特征

2025-10-010
OAAI
Methotrexate-Loaded Liposomal Formulation Enables 6-Week Sustained Intraocular Therapeutic Drug Release in a Porcine Model

甲氨蝶呤负载脂质体制剂在猪模型中实现6周持续眼内治疗性药物释放

2025-09-010
OAAI
Clinical presentation, management and outcome of TIAN in CNS lymphoma treated with CD19-CAR T-cell Therapy

TIAN的临床表现、管理及CD19-CAR T细胞治疗下在中枢神经系统淋巴瘤中的结局

Blood
IF23.1
2025-07-170
PRE
Utilization of universal-targeting mSA2 CAR-T cells for the treatment of glioblastoma

通用靶向mSA2 CAR-T细胞在胶质母细胞瘤治疗中的应用

2025-06-150
OAAI
CD70-specific CAR-T cell therapy for the treatment of glioblastoma
2024-03-220
PRE